Centre for NanoHealth

Transcription

1 Steve Conlan PhD An integrated collaborative base for businesses in Wales Director - Reproductive Biology & Cancer Research Institute of Life Science School of Medicine

2 Unique interdisciplinary R&D environment, based on the application of Nanotechnology, leading innovations in Healthcare Open access R&D facility based in a hospital environment Underpinned by interdisciplinary academic research excellence Assist and collaborate with companies in developing novel products + processes Establish a European Centre of Excellence for NanoHealth

3 Impact on Healthcare Diagnosing and treating diseases Enhancing early intervention Non-hospital environments Personalised Medicine

4 R&D Areas Diagnostics, Testing, Monitoring Imaging, Characterisation Computational and Mathematical Modelling Regenerative Medicine, Stem Cells Scale-up and Printing Safety and Testing of Nanomaterials

5 CNH Building opens Q Facilities available now Nano-suite Class 100/1000 dirty clean room Bio-clean room Nanostructure growth SEM & AFM/SNOM NMR & Rheology Printing and Coating Bio-suite NanoToxicology Cell Imaging Tissue Engineering Molecular biology Microbiology Direct access to: Clinical Trials Unit & Patient imaging (MRI&CT)

6 Institute of Life Science 2 Clinical Research Facility Research Imaging Health Services Research Business Incubation

7 The $1Billion Epigenetics market: a case study Epigenetics is the study of the heritable control of gene expression. Epigenetic changes are integral to normal development, and have been linked with several human diseases including cancer Discoveries in this area are expected to bring about major applications in the healthcare and treatment of diseases. To do this new tools and technologies need to be provided by the lifescience industry.

8 Market potential for growth Total world-wide sales revenues for epigenetics markets were $930 million in 2009, and are expected to increase to more than $6 billion in 2014, a compound annual growth rate (CAGR) of 45%. The largest epigenomic market segments in 2009 were pharmaceuticals and research tools. Pharmaceuticals revenues will increase from $590 million in 2009 to nearly $4 billion in 2014, a compound annual growth rate (CAGR) of 46%. Sales of epigenomics-based in-vitro diagnostics will experience high growth. This market segment was worth $27 million in 2009 and will increase at a 114% compound annual growth rate (CAGR) to reach a value of $1.2 billion in 2014 Biotechnology - Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics, Report Code: BIO059B, Published: March 2010

9 The Epigenetics Tools/Diagnostics Market Select BioSciences market survey identified the following key tools of epigenetic research Other 17% DNA microarrays 55% ChIP technology 42% Methylation-specific Enzymes Methylation-specific PCR Bisulfite Genome Sequencing 24% 29% 37% ChIP assays are the second most common technique despite their current complexity and limitations

10

11 Knowledge Transfer Partnership (KTP) Porvair Technology

12 A4B CIRP EpiGen: Next-generation epigenetics tools for lifescience & healthcare.

13 Global Networks/Global Investment EU, US, South America and Asia Celtic Alliance NanoHealth Alliance for Nanohealth

14 CNH & ILS 100 Million Technology and Innovation Investment Partnership with Dept Health and Welsh Government 250 Welsh companies directly assisted 50 research collaborations with industry and business 230 new jobs created 30 new companies established in the sector >11,000 square metres for research and business incubation Access to patient cohort of c600,000 Business engagement from Affiliate scheme to Client Organisation Nearly 25million investment triggered into Welsh sector

15 Steve Conlan +44 (0)